In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...

Cuts to U.S. foreign aid will endanger HIV treatment and prevention services globally and are likely to reverse decades of ...

South Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir, that research ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

A GNA feature by Laudia Sawer Tema, July 12, GNA - On any ordinary morning, Maame Esi, an HIV mentor mother, stands among other mothers at the antenatal clinic of the Tema General Hospital, scanning ...

The UCSF community is saddened at the passing of former UCSF faculty member William Rutter, PhD, whose collaborative and ...

A U.S. Agency for International Development funding freeze in January forced the closure of India’s Mitr Clinic, the ...

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...